Cargando…

Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form

The prominent human symbiont Bacteroides fragilis protects animals from intestinal diseases, such as ulcerative colitis, and its capsular polysaccharide plays a key role in reducing inflammation. B. fragilis strain ZY-312 was isolated from the feces of a healthy breast-fed infant, and the zwitterion...

Descripción completa

Detalles Bibliográficos
Autores principales: Zheng, Lijun, Luo, Meihua, Kuang, Gaobo, Liu, Yangyang, Liang, Debao, Huang, Haiqing, Yi, Xiaomin, Wang, Congfeng, Wang, Ye, Xie, Qiuling, Zhi, Fachao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751226/
https://www.ncbi.nlm.nih.gov/pubmed/33364945
http://dx.doi.org/10.3389/fphar.2020.570476
_version_ 1783625626601652224
author Zheng, Lijun
Luo, Meihua
Kuang, Gaobo
Liu, Yangyang
Liang, Debao
Huang, Haiqing
Yi, Xiaomin
Wang, Congfeng
Wang, Ye
Xie, Qiuling
Zhi, Fachao
author_facet Zheng, Lijun
Luo, Meihua
Kuang, Gaobo
Liu, Yangyang
Liang, Debao
Huang, Haiqing
Yi, Xiaomin
Wang, Congfeng
Wang, Ye
Xie, Qiuling
Zhi, Fachao
author_sort Zheng, Lijun
collection PubMed
description The prominent human symbiont Bacteroides fragilis protects animals from intestinal diseases, such as ulcerative colitis, and its capsular polysaccharide plays a key role in reducing inflammation. B. fragilis strain ZY-312 was isolated from the feces of a healthy breast-fed infant, and the zwitterionic capsular polysaccharide zwitterionic polysaccharide, TP2, was extracted. In rats with 2,4-dinitrobenzenesulfonic acid (DNBS)-induced enteritis, TP2 at an optimal dose of 2.5 mg/kg could significantly alleviate enteritis and reduced the degree of intestinal adhesions, the intestinal ulcer area, and the incidence of ulcers in rats. To understand the underlying mechanism, TP2 was labeled with Fluorescein isothiocyanate and orally administered at a dose of 2.5 mg/kg in rats. TP2 was mainly distributed in the cecum and colorectum, but it was not detected in the blood and other organs except that a compound with a molecular weight greater than that of TP2-FITC was found in liver tissue. During the absorption, distribution, metabolism, and excretion, TP2 was indigestible. These results were further confirmed by investigation in the simulated gastric, intestinal fluid, and colonic fluid with fecal microbiota in vitro, where TP2 remained unaltered at different time points. Furthermore, flora composition was analyzed in simulated colonic fluid with TP2 added and it was found that TP2 increased the abundance of Faecalibacterium, Enterococcus romboutsia, and Ruminococcaceae, whereas the abundance of the phylum Proteobacteria represented by Sutterella, Desulfovibrio, and Enterobacteriaceae was decreased. However, the amount of short-chain fatty acids in the simulated colonic fluid was not changed by intestinal flora post-TP2 addition. In conclusion, these findings confirmed that TP2, a capsular polysaccharide of B. fragilis, protects against ulcerative colitis in an undegraded form.
format Online
Article
Text
id pubmed-7751226
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-77512262020-12-22 Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form Zheng, Lijun Luo, Meihua Kuang, Gaobo Liu, Yangyang Liang, Debao Huang, Haiqing Yi, Xiaomin Wang, Congfeng Wang, Ye Xie, Qiuling Zhi, Fachao Front Pharmacol Pharmacology The prominent human symbiont Bacteroides fragilis protects animals from intestinal diseases, such as ulcerative colitis, and its capsular polysaccharide plays a key role in reducing inflammation. B. fragilis strain ZY-312 was isolated from the feces of a healthy breast-fed infant, and the zwitterionic capsular polysaccharide zwitterionic polysaccharide, TP2, was extracted. In rats with 2,4-dinitrobenzenesulfonic acid (DNBS)-induced enteritis, TP2 at an optimal dose of 2.5 mg/kg could significantly alleviate enteritis and reduced the degree of intestinal adhesions, the intestinal ulcer area, and the incidence of ulcers in rats. To understand the underlying mechanism, TP2 was labeled with Fluorescein isothiocyanate and orally administered at a dose of 2.5 mg/kg in rats. TP2 was mainly distributed in the cecum and colorectum, but it was not detected in the blood and other organs except that a compound with a molecular weight greater than that of TP2-FITC was found in liver tissue. During the absorption, distribution, metabolism, and excretion, TP2 was indigestible. These results were further confirmed by investigation in the simulated gastric, intestinal fluid, and colonic fluid with fecal microbiota in vitro, where TP2 remained unaltered at different time points. Furthermore, flora composition was analyzed in simulated colonic fluid with TP2 added and it was found that TP2 increased the abundance of Faecalibacterium, Enterococcus romboutsia, and Ruminococcaceae, whereas the abundance of the phylum Proteobacteria represented by Sutterella, Desulfovibrio, and Enterobacteriaceae was decreased. However, the amount of short-chain fatty acids in the simulated colonic fluid was not changed by intestinal flora post-TP2 addition. In conclusion, these findings confirmed that TP2, a capsular polysaccharide of B. fragilis, protects against ulcerative colitis in an undegraded form. Frontiers Media S.A. 2020-12-07 /pmc/articles/PMC7751226/ /pubmed/33364945 http://dx.doi.org/10.3389/fphar.2020.570476 Text en Copyright © 2020 Zheng, Luo, Kuang, Liu, Liang, Huang, Yi, Wang, Wang, Xie and Zhi http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Zheng, Lijun
Luo, Meihua
Kuang, Gaobo
Liu, Yangyang
Liang, Debao
Huang, Haiqing
Yi, Xiaomin
Wang, Congfeng
Wang, Ye
Xie, Qiuling
Zhi, Fachao
Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
title Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
title_full Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
title_fullStr Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
title_full_unstemmed Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
title_short Capsular Polysaccharide From Bacteroides fragilis Protects Against Ulcerative Colitis in an Undegraded Form
title_sort capsular polysaccharide from bacteroides fragilis protects against ulcerative colitis in an undegraded form
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7751226/
https://www.ncbi.nlm.nih.gov/pubmed/33364945
http://dx.doi.org/10.3389/fphar.2020.570476
work_keys_str_mv AT zhenglijun capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT luomeihua capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT kuanggaobo capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT liuyangyang capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT liangdebao capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT huanghaiqing capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT yixiaomin capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT wangcongfeng capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT wangye capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT xieqiuling capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform
AT zhifachao capsularpolysaccharidefrombacteroidesfragilisprotectsagainstulcerativecolitisinanundegradedform